Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 4/2011

01-08-2011

Palliative Medicine: Barriers and Developments in Mainland China

Authors: Jinxiang Li, Mellar P. Davis, Pamela Gamier

Published in: Current Oncology Reports | Issue 4/2011

Login to get access

Abstract

The development of palliative care in China is vital to the care of its aging population and associated increase in cancer incidence. There are physician-related and population-related barriers which impede palliative care development. The first institute for hospice care was established in Tianjin. Community hospices (Ning Yang Yuan) have been established by the Li Ka Shing Foundation. Academic centers such as the one in Chengdu associated with Sichuan University have partnered with the World Health Organization to establish centers of excellence to both develop and teach palliative care to physicians in training and practice. The National Hospice Service Program has developed five principles to the practice of palliative care in China.
Literature
1.
• Dong B, Ding Q. Aging in China: a challenge or an opportunity? J Am Med Dir Assoc. 2009;10(7):456–8. This study gives new important information on the status of the aging Chinese population, which means an increasing need for hospice care.PubMedCrossRef
2.
•• Zhao P, Dai M, Chen W, Li N. Cancer trends in China. Jpn J Clin Oncol. 2010;40(4):281–5. Chinese cancer incidence of 400/100,000 now are very important data, which should be a cause for concern.PubMedCrossRef
3.
4.
5.
Wang XS, Di LJ, Reyes-Gibby CC, Guo H, Liu SJ, Cleeland CS. End-of -Life Care in urban areas of China: a survey of 60 oncology clinicians. J Pain Symptom Manage. 2004;27(2):125–32.PubMedCrossRef
6.
Ye R, Lu Z, Xie Y, Wang C. National Textbook of Medicine for Medical Student. 6th ed. Beijing: People’s Medical House of China; 2004. p. 1–4.
7.
Chen J, Ding X, Liao L, Yang B, Weng X. Practicing Medicine, 11th edn. People’s Medical House of China; 2005, pp. 1–6.
8.
Lijun DI, Shujun L, Guohang S, Fengling W, Guangwei X. Investigation of the current status of palliative care of cancer patients in China and the clinicians’ attitude to palliative care of cancer patients. Chin J Clin Oncol Rehabil. 2003(5):7–11.
9.
• Yanjun S, Changli W, Ling W, Woo JL, Sabrina K, Chang L, et al. A survey on physician knowledge and attitudes towards clinical use of morphine for cancer pain treatment in China. Support Care Cancer. 2010;18(11):1455–60. This survey shows that Chinese physicians lack knowledge about morphine. Therefore, it is necessary to train medical staff and increase their awareness and knowledge of effective cancer pain management. PubMedCrossRef
10.
Tongdu LI. Present implementation situation and prospects of cancer pain control strategy in China. J Qilu Oncol. 2003(1):11–15.
11.
Liu Z, Zhou W, Lian Z, Mu Y, Cao J, Cai Z. A survey of attitudes, knowledge and clinical practice on cancer pain in Chinese health professionals. Chinese Journal of Pain Medicine. 1999(1):3–9.
12.
Tang W. Analysis on Suitable Usage of analgesics to the patients in advanced cancer. Herald of Medicine, 2005(06):86–88.
13.
Pang Z, Liu X, Wang J, Shi X. Pethidine can’t be used for cancer pain therapy for long time. Chinese Journal of Drug Dependence. 1998;7(4):246–8.
14.
Zhu S. An Analysis Annual Quantity both Pethidine and Morphine. Chinese Pharmaceutical Affairs. 2004;18(11):696–709.
15.
•• Shi Y, Wang G, Luo W, Wang Z, Li J. The status and policy research on palliative care in Chinese cities. Scientific and Educational Publishing House of Shanghai. 2010:14–17. This study demonstrates that patients with advanced cancer who are dying require many persons to care for them.
16.
• National Hospice Service Program by LKSF. Guidelines for hospice management. 2011:3–5. Ning Yang Yuan is a kind of palliative care in community supported by LKSF and is very important in the management of the terminally ill in China.
17.
Xue Y, Milone-Nuzzo P. Development of hospice in China. Caring. 2004;23(1):34–6.PubMed
18.
19.
Sun Y, Gu W. The World Health Organization 3-step analgesic ladder for cancer pain. Second edition. 2002:1–2.
20.
A Notice on the World Health Organization 3-step analgesic ladder for cancer pain Issued by Security Management Department of Chinese Drugs and Monitor Bureau. (DMS 1999–68). www.​hyey.​com/​Article . Accessed on January 18 2007.
21.
Sun Y, Gu W. The World Health Organization 3-step analgesic ladder for cancer pain: principle and guide, 1999:1–8.
22.
Li J, Twycross RG, Davis MP, Li P, Shuser J, Jiang J. Palliative Medicine. Beijing: People’s Medical House of China; 2005.
23.
• Li Ka Shing Foundation, Li Yu, Li Jinxiang, Wei Chen, Weihua Cao, Huiping Chen. Palliative medicine - symptom management in advanced cancer. Publishing House of Shantuo University. 2008:10–13. Mr. Li Ka Shing had the original concept of support for the poor with advanced cancer and is a wonderful example of charity in China.
24.
•• National hospice service program by LKSF. Guidelines for hospice menagement. 2011:3–10. The objectives and principles of NHSP are an important guidance to palliative care in the Chinese community.
Metadata
Title
Palliative Medicine: Barriers and Developments in Mainland China
Authors
Jinxiang Li
Mellar P. Davis
Pamela Gamier
Publication date
01-08-2011
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 4/2011
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-011-0169-9

Other articles of this Issue 4/2011

Current Oncology Reports 4/2011 Go to the issue

ReviewPaper

Emerging Therapeutic Targets for Soft Tissue Sarcoma

Clinical Trial Report

Adjuvant Whole-Brain Radiotherapy Versus Observation after Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study

ReviewPaper

The Evolving Role of Targeted Therapy in Early-Stage and Locally Advanced Non-small Cell Lung Cancer

ReviewPaper

Malignant Pleural Mesothelioma

ReviewPaper

Medical Treatment of Mesothelioma: Anything New?

ReviewPaper

Systemic Therapy Options for Unresectable and Metastatic Chordomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits